Articles tagged "Immunosuppression"

2022 American Transplant Congress
Immunosuppressants Alter Lymph Node Architecture and Create Distinct Microbiome Footprints
S. J. Gavzy¹, R. Lakhan², J. Iyyathurai², V. Saxena², L. Li², B. Ma², E. Mongodin², J. S. Bromberg²
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Maryland, Baltimore, MD
*Purpose: There are complex interactions among immunosuppressants, antibiotics, and the gut microbiome on the host immune system. Microbiota can alter lymph node (LN) structure and…
2022 American Transplant Congress
Adenosine A2A Receptor (A2AR) Agonist Apadenoson Promotes Survival in K28-hACE2 Mice and Syrian Hamsters Infected with Sars-CoV-2
P. Chhabra¹, B. Mann², M. Ma¹, S. Feldman³, J. Linden⁴, K. L. Brayman¹
¹Department of Surgery, University of Virginia Health System, Charlottesville, VA, ²Department of Infectious Diseases, University of Virginia Health System, Charlottesville, VA, ³Center for Comparative Medicine, University of Virginia Health System, Charlottesville, VA, ⁴Department of Nephrology, University of Virginia Health System, Charlottesville, VA
*Purpose: To determine if Apadenoson or Regadenoson has a therapeutic effect in attenuating hyper-inflammation and improving survival rate in K18-hACE2mice or Syrian hamsters infected with…
2022 American Transplant Congress
Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome
P. A. Jacobson¹, A. Saqr¹, B. Carlson¹, C. Staley², A. Rashidi³, S. Holtan³, M. Al-Kofahi¹, T. Kaiser², M. MacMillan⁴, J. Young⁵, N. El Jurdi³, D. Weisdorf³, A. Khoruts⁶
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Univ of MN, Dept of Surgery, Minneapolis, MN, ³Univ of MN, Divison of Heme/Onc Transplant, Minneapolis, MN, ⁴Univ of MN, Pediatric Heme/Onc Transplant, Minneapolis, MN, ⁵Univ of MN, Divison of Infectious Diseases, Minneapolis, MN, ⁶Univ of MN, Division of Gastroenterology, Hepatology and Nutrition, Minneapolis, MN
*Purpose: Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplant (HCT). Blood concentrations of mycophenolic acid (MPA) are highly variable and…
2022 American Transplant Congress
Comparative Case Study of Mycobacterium Infections in Pediatric Post Intestinal Transplant
S. Yerina¹, R. Kanthula¹, Y. Rekhtman², S. Kaufman¹, U. Ekong¹, N. Yazigi¹, T. Fishbein¹, A. Kroemer¹, C. Matsumoto¹, K. Khan¹
¹Transplant, Georgetown University Hospital, Washington, DC, ²GI and Nutrition, Prisma Health Midlands Children's Hospital, Columbia, SC
*Purpose: We describe two rare and challenging post pediatric intestinal transplant cases with both Mycobacterium (M) Abscessus and Mycobacterium (M) Immunogenum in post surgical site…
2022 American Transplant Congress
Optimizing Kidney Transplant Immunosuppression Using a Phenotypic Personalized Dosing Model
J. F. Bruner¹, N. Padmanabhan², C. Ho², A. Zarrinpar¹
¹Surgery, University of Florida, Gainesville, FL, ²Bioengineering, University of California, Los Angeles, Los Angeles, CA
*Purpose: Immunosuppression is essential for preventing rejection and promoting long-term graft survival following solid organ transplantation; it also places patients at risk for infection and…
2022 American Transplant Congress
Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients: Provisional Data Report of a Multicenter, Open-Label, Efficacy and Safety Study
A. Abdellatif¹, L. Zhao², K. Cherny², B. Marder², J. D. Scandling³, K. Saag⁴
¹Division of Nephrology, Baylor College of Medicine, Houston, TX, ²Horizon Therapeutics PLC, Deerfield, IL, ³Division of Nephrology, Stanford School of Medicine, Stanford, CA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
*Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase co-therapy with immunomodulators improved urate lowering therapy (ULT) response…
2022 American Transplant Congress
Early Clinical Experience With Nirmatrelvir/ritonavir For Treatment Of Covid-19 In Solid Organ Transplant Recipients
D. Salerno¹, D. Jennings², N. Lange³, D. Kovac¹, T. Shertel¹, J. Chen⁴, J. Hedvat⁵, J. Scheffert¹, R. S. Brown⁶, M. Pereira⁷
¹NewYork-Presbyterian Hospital, New York, NY, ²Long Island University, Brooklyn, NY, ³Pharmacy, NewYork-Presbyterian Hospital, New York, NY, ⁴Columbia University Irving Medical Center, Fort Lee, NJ, ⁵New York Presbyterian Hospital, Tenafly, NJ, ⁶Weill Cornell Medicine, New York, NY, ⁷New York Presbyterian Hospital, New York, NY
*Purpose: Nirmatrelvir/ritonavir use has not yet been described in solid organ transplant recipients (SOTR) who become infected with COVID-19. The objective of our study was…
2022 American Transplant Congress
Clinical Outcomes In A Large Transplant Cohort Hospitalized With COVID-19: Mycophenolate Mofetil (MMF) Utilization And Mortality Trends
R. L. Gottlieb¹, M. Askar², L. Chen³, A. Chandak⁴, E. Mozaffari³, M. Thrun³, R. Haubrich³
¹Baylor Scott & White Research Institute, Dallas, TX, ²Baylor University Medical Center, Dallas, TX, ³Gilead Sciences, Foster City, CA, ⁴Certara, New York, NY
*Purpose: To characterize demographics, treatment patterns, and outcomes among 3,998 transplant patients hospitalized for COVID-19 over 16 months of the pandemic (May ’20-Aug ’21).*Methods: Adult…
2022 American Transplant Congress
Liver Transplantation – Is There a Life After Death?
B. Dorobantu
General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
*Purpose: Organ donation and liver transplantation can transform the lack of hope and a terrible loss into a gift - new life that springs from…
2022 American Transplant Congress
Impact of Early versus Late Initiation of Sirolimus Regimens on Mortality After Kidney Transplantation: Age-Stratified Analyses of Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kingston, FL
*Purpose: Observational and meta-analytic studies have associated sirolimus with an increased risk of mortality in kidney transplant (KT) recipients (KTRs). We aimed to examine the…